StageLoan | Alive
Last Raised$100K | 3 yrs ago
About Saladax Biomedical
Saladax Biomedical develops and commercializes diagnostic assays for the practical delivery of personalized medicine. The company's line of MyCare assays improves the efficacy of existing drugs through optimized dosing. Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug dose management assays in various stages of development. Three MyCare assays are currently offered to the oncology community: My5-FU, MyPaclitaxel and MyDocetaxel. Saladax's MyCare line also serves the central nervous system (CNS) field, with two antipsychotic drug dose management assays.
Missing: Saladax Biomedical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Saladax Biomedical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Saladax Biomedical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Saladax Biomedical is included in 4 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Saladax Biomedical Patents
Saladax Biomedical has filed 27 patents.
The 3 most popular patent topics include:
Piperazines, Fluoroarenes, Piperidines, Atypical antipsychotics, Antidepressants
Piperazines, Fluoroarenes, Piperidines, Atypical antipsychotics, Antidepressants
Latest Saladax Biomedical News
Nov 2, 2022
Published ReStart and South London and Maudsley NHS Trust have joined forces to develop a new antipsychotic blood testing process for patients which delivers results within minutes. The new finger prick test, provided by Saladax Biomedical, reduces the need for traditional blood testing, cutting the time spent waiting for results from 5-10 days to around six minutes. South London and Maudsley has collaborated with integration and interoperability provider ReStart to connect systems across the whole Healthier South East London ICS and the wider LHCRE, One London. Now, results data can be moved quickly between collection devices, allowing it to be displayed in real time. This enables rapid clinical decision-making regarding dose adjustments, based on side effects and symptoms. The new process saves time and resources, with the potential to reduce inpatient bed stays to three weeks, instead of three months. Andy Meiner, Chief Revenue Officer, for ReStart said: “We are proud to be the interoperability provider to South London and Maudsley NHS Trust. “They remain the mental health experts within the NHS, spearheading ground breaking research which in turn improves patient outcomes, saves resources and shortens care journeys.” Having instantaneous results at the Point of Care (PoC) means that patients are better informed and show increased adherence and engagement with their treatment. This has led to improved patient outcomes. The work utilises TIE interoperability across data collection points, patient records and Cogstack AI results processing. Stuart MacLellan, chief information officer at South London and Maudsley said: “This new blood testing system has the potential to significantly reduce the length of inpatient stays. “This is invaluable given the significant demand for NHS mental health services now. “Not only does this test reduce pressure on services, it empowers patients, giving them more control around their care – ultimately improving outcomes. “We look forward to seeing the positive impact this can have across the NHS, as it continues to benefit our organisation. “This wouldn’t have been possible without interoperability provider ReStart, allowing results data to be seen in real time and supporting rapid clinical decision making.” Sal Salamone, founder and CEO of Saladax Biomedical, said: “The ability to partner with an outstanding organisation such as South London and Maudsley NHS Trust to implement our PoC device was an incredible opportunity to fulfil the vision for our company. “From the improved patient-friendly blood collection to providing immediate test results while the patient is present, will significantly improve patient care and the drug’s effectiveness. “In addition, this disruptive technology will dramatically impact the use and efficacy of clozapine drug treatment.” To aid this work, the South London and Maudsley team have created a visualisation display for the outputs of the PoC test results, giving clinicians direct access to results and the ability to calculate trends across defined time periods. Published studies show considerable benefits in financial, planning and patient outcomes related to this new test technique. Under the new testing and medication regime, patients can now be stabilised on clozapine at a much shorter time, saving thousands and improving patients’ lives. Join ReStart and Stuart MacLellan from South London and Maudsley to find out more about the ground breaking work at a webinar on November 25 at 12.30pm. Contact: email@example.com to learn more. 60
Saladax Biomedical Frequently Asked Questions (FAQ)
When was Saladax Biomedical founded?
Saladax Biomedical was founded in 2004.
Where is Saladax Biomedical's headquarters?
Saladax Biomedical's headquarters is located at 116 Research Drive, Bethlehem.
What is Saladax Biomedical's latest funding round?
Saladax Biomedical's latest funding round is Loan.
How much did Saladax Biomedical raise?
Saladax Biomedical raised a total of $49.86M.
Who are the investors of Saladax Biomedical?
Investors of Saladax Biomedical include Ben Franklin Technology Partners of Northeastern Pennsylvania, Fosun Pharmaceutical, GE Capital, Delaware Crossing Investment Group, Life Sciences Greenhouse of Central Pennsylvania and 5 more.
Who are Saladax Biomedical's competitors?
Competitors of Saladax Biomedical include AgaMatrix, Integrated Diagnostics, Foundation Medicine, Third Eye Diagnostics, EraGen Biosciences and 11 more.
Compare Saladax Biomedical to Competitors
People today suffer from stress and disturbed eating habits which can increase wastes in blood and cause interrupted blood flow. MC FAN is a blood fluidity measurement device (blood fluidity analyzer) which simulates capillary vessels. When a blood sample is applied to the analyzer, the condition of the blood can be displayed on the TV monitor in real time.
CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.
Tensys Medical Tensys has developed a continuous, non-invasive blood pressure monitoring technology for cardiac output assessment that is easy to administer and comfortable for the patient. San Diego, CA.
OOO Meditsynskaya elektronika (Medical electronics) is engaged in production of portable devices (glucometers) for noninvasive (painless) monitoring of blood sugar content in human blood.
Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr
NeuroDx addresses important unmet needs in the neurosurgical market. Their lead product, ShuntCheck, is an aid to the detection offlow in implanted cerebrospinal fluid (CSF) shunts.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.